clinical trial · NCT03038022
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
Heterozygous Familial HypercholesterolemiaMGL-3196 (resmetirom)Placebo
brief summary
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in participants with Heterozygous Familial Hypercholesterolemia (HeFH).
started
Feb 23, 2017
primary completion
Jan 15, 2018
completion
Jan 15, 2018
last updated
Dec 23, 2025
official title
A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo Controlled Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol